KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Research & Development (2016 - 2022)

TherapeuticsMD filings provide 12 years of Research & Development readings, the most recent being $1.1 million for Q3 2022.

  • On a quarterly basis, Research & Development fell 30.72% to $1.1 million in Q3 2022 year-over-year; TTM through Sep 2022 was $5.5 million, a 31.61% decrease, with the full-year FY2021 number at $7.1 million, down 32.07% from a year prior.
  • Research & Development hit $1.1 million in Q3 2022 for TherapeuticsMD, down from $1.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $7.0 million in Q1 2018 to a low of $1.1 million in Q3 2022.
  • Median Research & Development over the past 5 years was $2.7 million (2020), compared with a mean of $3.6 million.
  • Biggest five-year swings in Research & Development: grew 4.22% in 2018 and later tumbled 50.29% in 2020.
  • TherapeuticsMD's Research & Development stood at $6.8 million in 2018, then tumbled by 34.37% to $4.4 million in 2019, then tumbled by 45.98% to $2.4 million in 2020, then tumbled by 40.69% to $1.4 million in 2021, then fell by 21.69% to $1.1 million in 2022.
  • The last three reported values for Research & Development were $1.1 million (Q3 2022), $1.6 million (Q2 2022), and $1.4 million (Q1 2022) per Business Quant data.